Optruma (Raloxifene Hydrochloride)

Raloxifene, the active ingredient in Optruma, is a selective estrogen receptor modulator presented as an oral tablet for oral use. It treats osteoporosis in postmenopausal women and reduces the risk of invasive breast cancer in women at high risk. GNH USA supplies Optruma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Raloxifene acts on bone metabolism and estrogen‑dependent pathways to address several clinical conditions. - Osteoporosis: improves bone mineral density and lowers fracture risk in postmenopausal women. - Invasive breast cancer risk: decreases the incidence of invasive breast cancer in women identified as high‑risk. - Postmenopausal bone loss: helps maintain skeletal strength during the menopausal transition.

Raloxifene may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: transient warmth and sweating episodes. - Leg cramps: muscle tightness, often in the calves. - Swelling: mild peripheral edema. - Nausea: occasional upset stomach. - Headache: mild to moderate intensity. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung vessels. - Stroke: cerebrovascular accident risk. - Myocardial infarction: possible heart attack. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver function abnormalities: elevated enzymes indicating hepatic stress.

Before prescribing raloxifene, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Assess bone health: obtain baseline DEXA scan to gauge osteoporosis severity. - Evaluate breast cancer history: avoid use in women with active or past estrogen‑dependent breast cancer. - Monitor lipid profile: check cholesterol levels periodically. - Avoid use in pregnancy: contraindicated due to fetal risk; ensure effective contraception. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Raloxifene can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Estrogen therapy: may diminish raloxifene’s bone‑protective effect. - Tamoxifen: combined use can increase risk of thromboembolic events. - Warfarin: raloxifene may potentiate anticoagulant effect, raising bleeding risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole): elevate raloxifene plasma concentrations.

Moderate Interactions (Monitor Closely): - Statins: monitor lipid levels as raloxifene may affect cholesterol. - SSRIs: watch for additive dizziness or headache. - Diuretics: assess for changes in fluid balance and edema. - Glucocorticoids: consider combined impact on bone density. - Antacids containing aluminum or magnesium: may reduce raloxifene absorption.